David Scott Jones - 24 Jan 2024 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
SVP & Chief Commercial Officer
Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
24 Jan 2024
Net transactions value
-$201,951
Form type
4
Filing time
26 Jan 2024, 17:03:44 UTC
Previous filing
24 Jan 2024
Next filing
29 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $72,240 +5,600 +15% $12.90 43,562 24 Jan 2024 Direct
transaction EYPT Common Stock Options Exercise $18,582 +5,700 +13% $3.26 49,262 24 Jan 2024 Direct
transaction EYPT Common Stock Sale $142,554 -5,700 -12% $25.01 43,562 24 Jan 2024 Direct F1
transaction EYPT Common Stock Sale $140,068 -5,600 -13% $25.01 37,962 24 Jan 2024 Direct F2
transaction EYPT Common Stock Options Exercise $3,870 +300 +0.79% $12.90 38,262 25 Jan 2024 Direct
transaction EYPT Common Stock Options Exercise $978 +300 +0.78% $3.26 38,562 25 Jan 2024 Direct
transaction EYPT Common Stock Sale $7,500 -300 -0.78% $25.00 38,262 25 Jan 2024 Direct
transaction EYPT Common Stock Sale $7,500 -300 -0.78% $25.00 37,962 25 Jan 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Stock Option (Right to Buy) Options Exercise $0 -5,600 -23% $0.000000 18,625 24 Jan 2024 Common Stock 5,600 $12.90 Direct F3
transaction EYPT Stock Option (Right to Buy) Options Exercise $0 -5,700 -6.3% $0.000000 85,455 24 Jan 2024 Common Stock 5,700 $3.26 Direct F4
transaction EYPT Stock Option (Right to Buy) Options Exercise $0 -300 -1.6% $0.000000 18,325 25 Jan 2024 Common Stock 300 $12.90 Direct F3
transaction EYPT Stock Option (Right to Buy) Options Exercise $0 -300 -0.35% $0.000000 85,155 25 Jan 2024 Common Stock 300 $3.26 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.09. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.25. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3 The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020
F4 The option to purchase vests and becomes exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.